Literature DB >> 10899918

N-Acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system.

J H Neale1, T Bzdega, B Wroblewska.   

Abstract

In the progress of science, as in life, timing is important. The acidic dipeptide, N-acetylaspartylglutamate (NAAG), was discovered in the mammalian nervous system in 1965, but initially was not considered to be a neurotransmitter candidate. In the mid-1980s, a few laboratories revisited the question of NAAG's role in the nervous system and pursued hypotheses regarding its function that ranged from a precursor for the transmitter pool of glutamate to a direct role as a peptide transmitter. Since that time, NAAG has been tested against nearly all of the established criteria for identification of a neurotransmitter. It successfully meets each of these tests, including a concentrated presence in neurons and synaptic vesicles, release from axon endings in a calcium-dependent manner following initiation of action potentials, and extracellular hydrolysis by membrane-bound peptidase activity. NAAG is the most prevalent and widely distributed neuropeptide in the mammalian nervous system. NAAG activates NMDA receptors with a low potency that may vary among receptor subtypes, and it is a highly selective agonist at the type 3 metabotropic glutamate receptor (mGluR3). Acting through this receptor, NAAG reduces cyclic AMP levels, decreases voltage-dependent calcium conductance, suppresses excitotoxicity, influences long-term potentiation and depression, regulates GABA(A) receptor subunit expression, and inhibits synaptic release of GABA from cortical neurons. Cloning of peptidase activities against NAAG provides opportunities to study the cellular and molecular mechanisms by which synaptic NAAG peptidase activity is controlled. Given the codistribution of this peptide with a spectrum of traditional transmitters and its ability to activate mGluR3, we speculate that one role for NAAG following synaptic release is the activation of metabotropic autoreceptors that inhibit subsequent transmitter release. A second role is the production of extracellular glutamate following NAAG hydrolysis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10899918     DOI: 10.1046/j.1471-4159.2000.0750443.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  92 in total

1.  Molecular characterization of N-acetylaspartylglutamate synthetase.

Authors:  Ivonne Becker; Julia Lodder; Volkmar Gieselmann; Matthias Eckhardt
Journal:  J Biol Chem       Date:  2010-07-19       Impact factor: 5.157

2.  Modulation of GABAergic inhibition in the rat superior colliculus by a presynaptic group II metabotropic glutamate receptor.

Authors:  S A Neale; T E Salt
Journal:  J Physiol       Date:  2006-09-14       Impact factor: 5.182

Review 3.  Research applications of magnetic resonance spectroscopy to investigate psychiatric disorders.

Authors:  Stephen R Dager; Neva M Corrigan; Todd L Richards; Stefan Posse
Journal:  Top Magn Reson Imaging       Date:  2008-04

Review 4.  The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research.

Authors:  Benjamin T Ristau; Denise S O'Keefe; Dean J Bacich
Journal:  Urol Oncol       Date:  2013-12-08       Impact factor: 3.498

Review 5.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

6.  Intracerebroventricular administration of N-acetylaspartic acid impairs antioxidant defenses and promotes protein oxidation in cerebral cortex of rats.

Authors:  Carolina Didonet Pederzolli; Francieli Juliana Rockenbach; Fernanda Rech Zanin; Nicoli Taiana Henn; Eline Coan Romagna; Angela M Sgaravatti; Angela T S Wyse; Clóvis M D Wannmacher; Moacir Wajner; Angela de Mattos Dutra; Carlos S Dutra-Filho
Journal:  Metab Brain Dis       Date:  2009-03-18       Impact factor: 3.584

7.  Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.

Authors:  Maria Traka; Robert L Wollmann; Sonia R Cerda; Jason Dugas; Ben A Barres; Brian Popko
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

8.  Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme.

Authors:  Jesse Alt; Marigo Stathis; Camilo Rojas; Barbara Slusher
Journal:  FASEB J       Date:  2013-03-23       Impact factor: 5.191

9.  Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization.

Authors:  Cyril Barinka; Youngjoo Byun; Crystal L Dusich; Sangeeta R Banerjee; Ying Chen; Mark Castanares; Alan P Kozikowski; Ronnie C Mease; Martin G Pomper; Jacek Lubkowski
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

10.  Excitatory neurotransmitters in brain regions in interictal migraine patients.

Authors:  Andrew Prescot; Lino Becerra; Gautam Pendse; Shannon Tully; Eric Jensen; Richard Hargreaves; Perry Renshaw; Rami Burstein; David Borsook
Journal:  Mol Pain       Date:  2009-06-30       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.